Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Dec 1.

Published in final edited form as: Kidney Int. 2013 Mar 27;83(6):1136–1143. doi: 10.1038/ki.2013.57

Table 2.

Demographics and clinical characteristics by haptoglobin median split taken at time of haptoglobin measurement.

	Haptoglobin Level
	Lower (n=102)	Upper (n=102)	P-value^*
Age^† (years)	59.5	58.7	0.3201
Diabetes Duration^† (years)	11.4	10.8	0.8916
Time to Biomarker^‡ (years)	1.1	1.1	0.9074
Male^† (%)	92.2	99.0	0.0170
non-Hispanic white^† (%)	68.6	55.9	0.0604
Intensive Treatment Group^† (%)	52.9	49.0	0.5753
Current Smoker^† (%)	16.7	17.7	0.8527
Biomarker Follow-up (years)	4.8	4.6	0.4220
ACE (%)	67.7	57.8	0.1476
Hemoglobin A1c (%)	7.7	7.9	0.1702
Creatinine (mg/dl)	1.0	1.0	0.2400
eGFR (ml/min)	84	86	0.4938
ACR^**(mg/g)	11	16	0.0106
Body Mass Index (kg/m²)	31.6	33.3	0.0354
SB Pressure (mmHg)	126	131	0.0142
DB Pressure (mmHg)	72	76	0.0037

^*

Chi-square or Kruskal-Wallis Test;

^†

Values at baseline VADT.

^‡

Time to Biomarker is the time from VADT baseline examination to collection of the samples for haptoglobin measurement;

^**

Geometric mean